trial · primary record
Jaktinib Hydrochloride Tablet
Atopic Dermatitis
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 207 |
| Primary completion | 2026-03-12 |
| Primary endpoint | Number and percentage of subjects with treatment emergent adverse event (TEAE) |
| Registry ID | NCT05676242 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:10.115Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05676242
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Jaktinib Hydrochloride Tablet · compound